Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.

MLA

Hong, Lingzhi, et al. “Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 15, no. 9, Sept. 2020, pp. 1449–59. EBSCOhost, https://doi.org/10.1016/j.jtho.2020.04.026.

APA

Hong, L., Negrao, M. V., Dibaj, S. S., Chen, R., Reuben, A., Bohac, J. M., Liu, X., Skoulidis, F., Gay, C. M., Cascone, T., Mitchell, K. G., Tran, H. T., Le, X., Byers, L. A., Sepesi, B., Altan, M., Elamin, Y. Y., Fossella, F. V., Kurie, J. M., … Zhang, J. (2020). Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 15(9), 1449–1459. https://doi.org/10.1016/j.jtho.2020.04.026

Chicago

Hong, Lingzhi, Marcelo V Negrao, Seyedeh S Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M Bohac, Xiaoke Liu, et al. 2020. “Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 15 (9): 1449–59. doi:10.1016/j.jtho.2020.04.026.